Figure 1 | Scientific Reports

Figure 1

From: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

Figure 1

A single PT302 s.c. administration provides sustained levels of Exendin-4 in plasma, whose Cmax and AUC is increased linearly in a dose-dependent manner. PT302, a sustained release formulation of Exendin-4, contains a mixture of polymers (98%) and Exendin-4 (2%). Time-dependent plasma levels of Exendin-4 were quantified by ELISA after (a) injection of three doses of s.c. PT302 (equivalent to 2.4, 4.8 and 9.6 mg/kg Exendin-4) into separate cohorts of 9 week old male Sprague-Dawley rats (n = 6 per group, blood sampled at 0, 0.5, and 1 hr after injection, as well as on days 1, 3, 5, 7, 9, 11, 14, 18, 21, and 26 post-injection). (b) Based on these pharmacokinetics studies, a PT302 dose equivalent to 2.0 mg/kg Exendin-4 was then evaluated in a separate series of alike rodents.

Back to article page